TICKERNERD
Menu
CGENCGENHealthcare · Biotechnology

CGEN Stock Forecast: Compugen Ltd. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.47
+0.41% on the day

The 5 Wall Street analysts covering Compugen Ltd. hold a median 12-month price target of $4 — +61.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$234.0M
Ticker Nerd rank
81 / 100
Median analyst target
$4.00
Analysts covering
5
Revenue$2.6M+107.0% y/y
Operating income−$8.8M
Net income−$7.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.5%
1M
+2.9%
YTD
+61.4%
1Y
+76.4%
From 52W high
−20.3%
From 52W low
+85.7%
$1.33
$3.10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CGEN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Compugen Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
81 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
100
Momentum
75
Revisions
73
Quality
72
Size
66
Value
61
Volatility
50
Issuance
48
Accruals
21

Growth (100): Sales and profits are climbing, and climbing faster than before.

Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26CGENHigh $6.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $4.00Median $4.00High $6.00

The green dot is the last close — the median target sits +61.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 May 2026Leerink PartnersMaintainsOutperform$13 → $5.00
7 Apr 2026Lake StreetInitiatesBuy—
7 Jan 2026HC Wainwright & Co.InitiatesBuy—
21 May 2024Truist SecuritiesMaintainsBuy—
8 Mar 2024Truist SecuritiesMaintainsBuy—
19 Dec 2023StifelMaintainsBuy—
23 Aug 2023Truist SecuritiesReiteratesBuy—
7 Aug 2023EF HuttonReiteratesBuy—
6 June 2023EF HuttonReiteratesBuy—
26 May 2023EF HuttonReiteratesBuy—
24 May 2023EF HuttonReiteratesBuy—
16 May 2023OppenheimerMaintainsOutperform—
28 Feb 2023OppenheimerReiteratesOutperform—
8 Feb 2023JefferiesDowngradeUnderperform—
5 Jan 2023EF HuttonInitiatesBuy—
15 Nov 2022OppenheimerMaintainsOutperform—
23 Aug 2022Truist SecuritiesMaintainsBuy—
8 Aug 2022JMP SecuritiesMaintainsMarket Outperform—
8 Aug 2022OppenheimerMaintainsOutperform—
5 Aug 2022JefferiesDowngradeHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CGEN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CGEN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Compugen Ltd. returned +76.4% against +17.5% for the S&P 500, dividends included.

CGEN vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Oct 25Jan 26Apr 26Jul 26CGENS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Compugen Ltd. (CGEN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
6.5×

Cheaper than 64% of US stocks

Price / sales
3.2×

Cheaper than 39% of US stocks

Price / book
2.6×

Cheaper than 36% of US stocks

EV / EBITDA
3.6×

Cheaper than 55% of US stocks

Growth & margins
Revenue growth (YoY)
107.0%

Higher than 93% of US stocks

Earnings growth (YoY)
107.0%

Higher than 84% of US stocks

Gross margin
−3.5%

Higher than 4% of US stocks

Operating margin
−339.6%

Higher than 9% of US stocks

Net margin
47.6%

Higher than 96% of US stocks

Returns & dividend
Return on equity
50.6%

Higher than 93% of US stocks

Return on assets
15.5%

Higher than 97% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Compugen Ltd. (CGEN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Compugen Ltd. has a market value of $234.0M and an enterprise value of $111.7M.

  • Revenue in the twelve months to 30 June 2026: $74.0M. The latest quarter grew 107.0% year on year.

  • Net income over the same four quarters: $35.2M, a 47.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.38.

  • Shares outstanding: 94.7M.

  • Trailing P/E: 6.5×; forward P/E: −6.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Compugen Ltd. employs 75 people — $987K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

CGEN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CGENCompugen Ltd.$234.0M
81
ALECAlector, Inc.$233.6M
41
WHWKWhitehawk Therapeutics, Inc.$234.3M
71
IVVDInvivyd, Inc.$231.4M
19
RNACCartesian Therapeutics, Inc.$240.0M
24
GLSIGreenwich LifeSciences, Inc.$226.8M
38
ELDNEledon Pharmaceuticals, Inc.$225.9M
36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Compugen Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CGEN news & analysis

Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

PRNewsWire · 8 Sept 2026neutral

Compugen Ltd., based in Holon, Israel, announced that it will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 8, 2026. The event provides an opportunity for the company's leadership to present to investors.

Why it matters — This participation offers Compugen visibility and a platform to communicate its progress and strategy to the investment community at a major industry conference.

All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy

Zacks Investment Research · 31 Aug 2026positive

Compugen (CGEN) was upgraded to a Zacks Rank #2 (Buy) by Zacks Investment Research, reflecting growing optimism about the company's earnings prospects. The upgrade suggests the stock may move higher on this improved outlook.

Why it matters — A Compugen watcher would care because the upgrade signals increased confidence from analysts in the company's near-term earnings potential.

Are Medical Stocks Lagging Compugen (CGEN) This Year?

Zacks Investment Research · 21 Aug 2026neutral

This Zacks Investment Research piece compares how Compugen (CGEN) and Envoy Medical (COCH) have performed relative to their sector so far this year. It provides a year-to-date performance review of the two medical stocks against their group.

Why it matters — CGEN watchers would want to see how the company's stock performance compares with its sector peers so far this year.

Compugen: Better Runway Ahead Of MAIA

Seeking Alpha · 7 Aug 2026positive

The article notes that Compugen has improved its cash runway to support operations into 2029, which should carry the company through the interim analysis of the MAIA trial. It identifies MAIA as the main value driver and suggests that a positive randomized readout could help validate COM701 and the broader PVRIG approach.

Why it matters — A longer runway reduces near-term financing risk and better positions CGEN to reach its key MAIA clinical data milestone.

Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 3 Aug 2026neutral

Seeking Alpha published the transcript of Compugen Ltd.'s (CGEN) Q2 2026 earnings call. The item is a transcript of the company's second-quarter 2026 earnings call.

Why it matters — A CGEN watcher would care because earnings-call transcripts provide management's commentary on quarterly results and company outlook.

FAQ

Frequently asked questions about CGEN stock

What is the CGEN stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Compugen Ltd. have a median 12-month price target of $4, with estimates ranging from $4 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CGEN stock a buy right now?

Of the 5 analysts covering Compugen Ltd., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Compugen Ltd. 81 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CGEN?

As at 12 Sept 2026, Compugen Ltd. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (100 of 100).

Will CGEN stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +61.9% from the last close, and Ticker Nerd's factor model ranks Compugen Ltd. 81 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CGEN stock forecast for 2030?

No analyst covering Compugen Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.

How has CGEN stock performed over the past year?

Compugen Ltd. returned +76.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Compugen Ltd. do?

Compugen Ltd. is a clinical-stage therapeutic discovery and development company focused on cancer immunotherapy and autoimmune diseases.

What is the latest news on CGEN?

The most recent item we track (PRNewsWire, 8 Sept 2026): "Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference". Compugen Ltd., based in Holon, Israel, announced that it will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 8, 2026. The event provides an opportunity for the company's leadership to present to investors.

Company

About Compugen Ltd.

Compugen Ltd. is a clinical-stage therapeutic discovery and development company focused on cancer immunotherapy and autoimmune diseases. Compugen Ltd. uses its AI- and machine learning-powered Unigen platform to identify novel drug targets, validate biological pathways, and advance therapeutic and diagnostic biomarker candidates. Its current work centers on developing antibodies and other biologic product candidates for oncology and immune-related conditions, with programs designed to address unmet needs in solid tumors and inflammatory diseases. The company operates across Israel, the United States, and Europe, supporting research, development, and commercial collaboration activities. Headquartered in Holon, Israel, Compugen Ltd. plays a role in the biotechnology market as a platform-driven company that combines computational discovery with experimental development to build differentiated drug candidates.

CEO Dr. Eran Ophir Ph.D. · 75 employees · Israel · https://cgen.com